EMA - PRIME enables earlier availability of life-changing medicines

10th March 2022

EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that address patients’ unmet medical needs. The time to marketing authorisation was reduced for medicines that benefitted from PRIME support, giving patients earlier access to transformative treatments that can make a real difference to their health.

Read More

Back to News Archive